Cellular traffic camera catches a pileup on the metabolic highway

From the Sullivan Lab, Human Biology Division

The cell is a bustling place, metabolically speaking. Reactions occur in less than a second, and any disruption to the metabolite network might have quick and far-reaching impacts. With a multitude of reactions happening simultaneously, studying metabolism is famously challenging.

In a new paper in Nature Metabolism, researchers from the lab of Dr. Lucas Sullivan in the Human Biology Division made use of a tool previously developed by the lab to understand metabolic flux in real-time using live-cell imaging. The study was led by co-authors Dr. Madeleine Hart, now a postdoc at the Van Andel Institute, and David Sokolov, who recently defended his PhD thesis.

The research focused on aspartate, which is a crucial node in several metabolic networks. Aspartate in one form is an amino acid required for protein synthesis. In other pathways, aspartate is a critical precursor of the pyrimidines and purines that form the building blocks of DNA and RNA.

Previous work from Dr. Sullivan and his group has shown that mitochondrial dysfunction in certain cancers creates bottlenecks in metabolic networks that only aspartate can rescue. In other words, aspartate is a vitally important growth-limiting metabolite, and aspartate levels can impact oncogenesis as well as cell stress responses, hematopoietic regeneration, and T cell biology.

“We have spent a lot of time characterizing when aspartate inhibition is a problem,” explains Dr. Sullivan.

For most of that time, they’ve relied on the standard technique of breaking open cells and extracting metabolites for analysis using mass spectrometry. While this approach is sensitive and comprehensive, it has downsides.

“It's destructive, it's expensive, it's one time point at a time,” says Dr. Sullivan.

“The metaphor that I use when I talk about this whole approach is a city,” adds Dr. Sokolov. “All the roads are pathways and all the cars on the roads are metabolites. Mass spectrometry is akin to taking a photo of Seattle from above: it’s comprehensive but not dynamic. You could take a bunch of pictures for a sense of how traffic flow changes over time, but pictures are expensive to take in this scenario.”

Instead, the Sullivan Lab made elegant use of an aspartate biosensor that they developed and characterized in 2023. (We featured the publication where the Sullivan Lab first described this biosensor in a previous Science Spotlight article.)

The aspartate biosensor is a modified green fluorescent protein (GFP) that only fluoresces in the presence of aspartate. Using cells with red fluorescent nuclei and a live cell imager allows real-time tracking of both aspartate levels and cellular proliferation rates.

"In the city analogy, the biosensor works like a video,” explains Dr. Sokolov, “but a video that only shows the green, ‘aspartate’ cars moving.”

Video of fluorescent cells
Video of GFP biosensor of aspartate levels. Nuclei are tagged in red. Image provided by study authors.

In cells grown under normal conditions, the biosensor showed a perfect movie of metabolic homeostasis: aspartate levels remained high while the cells steadily proliferated. After 48 hours, cell division slowed as the cells grew crowded, and aspartate levels started decreasing as nutrients in the media were expended.

To understand what happens during conditions of aspartate limitation, the authors focused on one of their favorite enzymes: succinate dehydrogenase (SDH). SDH is lost in many cancers and mitochondrial disorders, disrupting key processes involved with cellular energy production. The consequences of SDH loss are many but notably involve both aspartate depletion and succinate build-up.

When the authors chemically inhibited SDH, disrupting aspartate synthesis, they observed an interesting result: aspartate levels first plummeted (as expected), but then they went back up. Despite aspartate rebound, cell proliferation never recovered.

There could be two explanations for the rebound of aspartate in SDH-inhibited cells: 1) the cells may be increasing aspartate acquisition, or 2) there is decreased consumption through the pathways that normally use aspartate.

“We had no idea what was going on for 6 months and were wondering ‘how could we possibly explain this?’” Dr. Sullivan continues. “We did mass spectrometry to make sure it wasn’t an artifact.”

Not only did this mass spectrometry confirm the biosensor observations, it found a surprising impact of this aspartate rebound: in SDH-inhibited cells, there was a striking decrease in pyrimidine levels.    

“It was very unclear why there would be this specific deficiency in pyrimidine biosynthesis,” says Dr. Sullivan. “So, we did what all good scientists would do, and we looked through the literature.”

This literature search revealed an unexpected source of insight: an enzyme that’s been studied since the 70s. Enter aspartate transcarbamylase (ATCase), which directly converts aspartate into pyrimidine intermediates. This reaction is the first step in pyrimidine biosynthesis.

“E. coli ATCase has been a workhorse of molecular biology since the 70s and 80s,” explains Dr. Sullivan.

Intriguingly, succinate—which builds up in SDH-inhibited cells—can inhibit the activity of ATCase, at least in E. coli.

“It was lucky for us that people had been studying this particular enzyme for a long time,” adds Sokolov. He was tasked with proving the hypothesis that succinate build-up inhibits human ATCase.

“We needed to go back in time and do some old-fashioned biochemistry,” he says. “And I couldn’t have done this without the help of others at the Hutch. I was going door to door, getting all these random reagents with the goal of expressing human ATCase.”

These collaborations paid off in a big way. The authors showed that indeed succinate can inhibit the ability of human ATCase to consume aspartate.

“The lightbulb moment was when I did the enzyme activity assay, and the wells with added succinate showed a visible decrease in ATCase activity” he continues. "It's still wild to me that you can take an enzyme and feed it substrate, and it knows what to do.”

To confirm this mechanism in cells, they returned to their SDH-inhibited cells and treated with additional inhibitors that reduced succinate concentrations. With lower succinate levels in the cell, ATCase activity was restored, and aspartate levels fell as expected.

To sum up the biochemistry: SDH deficiency initially causes a drop in aspartate levels and a pile up of succinate. The excess succinate inhibits ATCase, and this prevents aspartate conversion to pyrimidines. All this leads to an eventual rebound of aspartate levels.

Graphical summary of model.
Model of study. At basal conditions, aspartate (purple circles) and succinate (yellow squares) are in homeostasis with high aspartate level. Upon SDH inhibition, aspartate levels decrease while succinate levels increase, ultimately reducing pyrimidine synthesis and resulting in replication stress. Chronic SDH impairment results in aspartate rebound and may require cellular adaptations. Image adapted from original study.

"Because SDH deficiency—which is a cancer relevant phenotype—causes this specific deficiency in pyrimidine capacity, these cells are intrinsically vulnerable to replication stress,” explains Dr. Sullivan. “It implies that this aspartate-succinate-pyrimidine axis could confer a specific vulnerability to replication stress inhibitors.”

This finding is incredibly relevant to SDH-mutated cancers. The authors recruited more collaborators at Fred Hutch to help them understand the in vivo ramifications of SDH loss in cancer.

“The other big unlock was that we worked with the MacPherson Lab to build a mouse model,” Dr. Sulivan says.

They found that SDH-limited cancers replicated the results from cell culture. This is very exciting, as it suggests that SDH-deficient tumors have unique vulnerabilities that might be therapeutically targeted.

“SDH deficiency causes all these problems, but the cells can adapt,” explains Dr. Sullivan. “How do they alter their metabolism to tolerate this metabolic state?”

“And can we target that somehow?” asks Dr. Sokolov.

In the metaphor of the cell as a city, SDH loss is like the shutdown of a major arterial road (Revive I5, anyone?). Cancer cells that can ‘re-route’ metabolic traffic through other thoroughfares survive, but they become more susceptible to blockages of those alternative routes.

“Cells that play metabolic whack-a-mole run out of options pretty quick,” Dr. Sullivan says.

Future work by the lab will investigate ways to exploit these weaknesses to metabolically ‘gridlock’ cancer cells and shut them down for good.


The spotlighted research was funded by a Public Health Services Ruth L. Kirschstein National Research Service Award, a Paul Neiman Graduate Student Award, a pilot award from the Human Biology Division at Fred Hutchinson Cancer Center, and the National Institutes of Health.

Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium Members Drs. David MacPherson and Lucas Sullivan contributed to this research.

Hart ML, Sokolov D, Danquah S, Zheng E, Doan AD, Davidsen K, MacPherson D, Sullivan LB. 2026. Succinate dehydrogenase loss suppresses pyrimidine biosynthesis via succinate-mediated inhibition of aspartate transcarbamylase. Nat Metab. doi: 10.1038/s42255-026-01524-w.

Hannah Lewis

Hannah Lewis is a postdoctoral research fellow with Jim Boonyaratanakornkit’s group in the Vaccine and Infectious Disease Division (VIDD). She is developing screens to find rare B cells that produce protective antibodies against human herpesviruses. She obtained her PhD in molecular and cellular biology from the University of Washington.